Cytogen KRX:217330KOSDAQ
싸이토젠 · Korean news coverage and regulatory filings, organized.
Articles, 24h3
Articles, 7 days3
DART filings, 7 days0
Articles tracked3since Sep 11
In Q2 2026, Cytogen reported revenue of ₩6.8bn, up 8.7% year on year, and an operating loss of ₩1.2bn. Cytogen (싸이토젠) appeared in 3 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 15 with 3 articles.
Cytogen quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩6.8bn | +8.7% | −₩1.2bn | −₩2.2bn |
| Q1 2026 | ₩6.4bn | +14.0% | −₩1.5bn | −₩1.3bn |
| Q4 2025 derived | ₩6.5bn | +17.2% | −₩2.6bn | −₩5.5bn |
| Q3 2025 | ₩7.6bn | +128.5% | −₩1.3bn | −₩1.6bn |
| Q2 2025 | ₩6.3bn | +426.6% | −₩1.9bn | −₩2.8bn |
| Q1 2025 | ₩5.6bn | +605.8% | −₩2.4bn | −₩2.4bn |
| Q4 2024 derived | ₩5.6bn | +548.0% | −₩1.9bn | −₩8.3bn |
| Q3 2024 | ₩3.3bn | +373.2% | −₩2.2bn | −₩2.9bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Cytogen top stories 2 weeks, by number of outlets
- 1
Latest Cytogen news Korean headlines
-
싸이토젠, 국가 R&D 과제 2건 동시 선정…CTC 기반 ‘진단→치료’ 밸류체인 확장
2 more on this story · 2 outlets
- 싸이토젠 “국가 혁신형 R&D 과제 2건 동시 선정”서울경제 · 09:41
- 싸이토젠, CTC 기반 국가 R&D 2건 선정… 치료·혈액정화로 영역 확장머니투데이 · 10:34